Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Three Major Trials With Zactima (Vandetanib) Reported
Please Note: While this is Still Excellent Background Info, New Treatments and Procedures Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

As a general rule, companies don't sit on great news with their drugs. Without any insider knowledge, this was my concern about why we hadn't heard anything about the results of three major lung cancer trials with the agent Zactima (vandetanib), which I had written a post about 8 months ago (see prior post about these trials with Zactima, an oral agent that inhibits both VEGF, a major mediator of angiogenesis, and the EGFR pathway). The recent lung cancer meeting in Chicago would have been the opportunity to present the results, but that meeting passed, and then some rather tepid results (here) were just reported less than a week after the meeting ended. Go figure... To review, zactima has activity in NSCLC, as reviewed in my first post on the agent. The four large trials that were launched include the following comparisons in previously treated patients with advanced NSCLC: 1) second line treatment with taxotere (docetaxel) alone vs. docetaxel/zactima, a large phase III trial (ZODIAC) 2) second line treatment with alimta (pemetrexed) alone vs. alimta/zactima, a large phase II randomized trial ZEAL) 3) second or third line treatment with zactima vs. tarceva (erlotinib), a large phase III trial (ZEST) 4) zactima vs. placebo in previously treated patients, a large phase III trial (ZEPHYR)

The early report described results from the first three trials, since the last has taken longer to accrue (again, we know that placebo-controlled trials are very slow to accrue in the US, and probably increasingly so outside of the US as well now). We learned that the response rates in the two trials of chemo +/- zactima were higher with the combination, but that overall survival trended positive but wasn't significantly better in either trial. Progression-free survival (PFS), which was the primary endpoint in the larger ZODIAC trial with taxotere, was significantly better with zactima on the taxotere trial but just trended toward positive in the alimta trial. Many clinicians had expressed some concern that even if PFS was significantly better in both, an absence of an overall survival benefit would really leave us questioning the value of the agent and whether the FDA will/would approve it. In the trial that directly compares zactima to tarceva head to head, we learned that zactima wasn't significantly better in any efficacy parameters, but it did show equivalent efficacy in an analysis of "non-inferiority" -- so it could officially be considered a tie. And there were reportedly no significant side effect issues, although we'll really need to see the full data. It's fair to say that this wasn't a home run, but there were certainly some positive leads. It's encouraging to see improved response rates and progression-free survival with chemo, even if OS wasn't clearly better. It's possible that we'll learn that some subgroups fared much better with zactima than others. And if zactima performs comparably to tarceva, the latter is an agent that we've been happy to have in our arsenal and part of the short list of agents that has been shown to improve survival significantly in previously treated patients. The FDA could decide that there are too few agents right now for previously treated patients, especially since both taxotere and alimta are both approved as first line therapies in advanced NSCLC, leaving us with very limited choices for patients who received one of these agents previously. In addition, alimta is not active in patients with squamous cancers, so the list of active options for the 30% of patients with squamous NSCLC is even shorter. Any new agent with activity is welcome. And if the ZEPHYR trial comparing zactima to placebo actually shows a survival benefit, I think this will bolster the argument that this agent has really earned its place. The entire lung cancer community would welcome any new active drugs in this setting.

Next Previous link

Previous PostNext Post

Related Content

Image
Patient Education Ambassadors 2023-24
Video
  Dr. Gladys Rodriguez and Hannah Manella, RD, discuss addressing nutritional concerns of patients who are undergoing cancer care.  
Image
Head And Neck Cancer Program
Video
Drs. Shetal Patel, Siddharth Sheth, and Jared Weiss discuss the most recent advances in head and neck cancer treatment, including curable and incurable head and neck cancers, thyroid cancers, and HPV positive and negative cancers.  

Forum Discussions

Canyil, I'm sorry your father and you are going through this. While we can't give urgent help we are her to help offer info and resources to help make the best...

Hello and welcome to Grace.  I'm sorry you're going through this worry.  It is normal to watch a small very slow-growing solid nodule with once-a-year CT scans.  Anything less than a...

Thanks you very much. So in summary the course of action taken suggested by lung specalist (re scan in 12 months) seems appropriate? And a PET at this stage is probably...

I can't say what is appropriate for you that's only something your professionals with all your information can do.  However, when someone has a solid nodule less than a cm that...

A doctor wouldn't nor shouldn't suspect a pancoast tumor with the info you've given.  It's like being in Colorado and hearing hoof beats and assuming it is zebras and not horses. ...

Hello and welcome to Grace.  I'm sorry you're worrying about this but it probably isn't cancer. 

 

From Adenocarcinoma of the lung: from BAC to the future, "GGNs with diameter...

Recent Comments

JOIN THE CONVERSATION
Canyil, I'm sorry your…
By JanineT GRACE … on
I can't say what is…
By JanineT GRACE … on
Thanks you very much. So in…
By razp on
A doctor wouldn't nor…
By JanineT GRACE … on